title: Esophagoprotective potential of cisapride. An additional benefit for gastroesophageal reflux disease.
abstract: Cisapride is a novel prokinetic agent that releases acetylcholine at the level of the myenteric plexus. Acetylcholine also plays a role in the secretory function of salivary glands evoked by intraesophagal mechanical and chemical stimulation, mediated through the esophagosalivary reflex. The impact, however, of cisapride on salivary protective components mediated by esophagosalivary reflex remains unknown. Therefore, we have studied salivary pH, bicarbonate, nonbicarbonate, glycoconjugate, protein, EGF, TGF-alpha, and PGE2 before and after the administration of cisapride. The study was conducted in 20 asymptomatic volunteers (9 women and 11 men, mean age 36, range 26-52). Salivary secretions were collected under basal conditions and during masticatory, mechanical, and chemical stimulation before and after four days of cisapride administration (10 or 20 mg four times a day). Cisapride administration resulted in a 45% increase in salivary volume during the basal condition (P < 0.01), a 32% increase during mastication (P < 0.05), a 53% increase during mechanical (P < 0.05), and a 51% increase during chemical (P < 0.01) stimulation. Cisapride administration resulted also in a significant increase in salivary protein output (P < 0.05), salivary bicarbonate (P < 0.05), and nonbicarbonate buffers (P < 0.05), and salivary EGF (P < 0.05). Salivary glycoconjugate significantly increased only during mechanical stimulation with the catheter and at the end of the esophageal perfusion procedure (P < 0.05). Although a similar trend was also recorded during the analysis of salivary PGE2, this difference did not reach statistical significance. Salivary pH and TGF-alpha before and after cisapride administration remained unchanged. The stimulatory impact of cisapride on salivary volume and inorganic (bicarbonate and nonbicarbonate buffers) and organic (protein, glycoconjugate, and EGF) protective components would benefit patients with GERD and would also be potential therapy for xerostomia.
authors.affiliation: University of Kansas Medical Center, Kansas City 66160, USA.
authors.forename: G F
authors.initials: GF
authors.lastname: Goldin
authors.forename: M
authors.initials: M
authors.lastname: Marcinkiewicz
authors.forename: T
authors.initials: T
authors.lastname: Zbroch
authors.forename: L P
authors.initials: LP
authors.lastname: Bityutskiy
authors.forename: R W
authors.initials: RW
authors.lastname: McCallum
authors.forename: J
authors.initials: J
authors.lastname: Sarosiek
mesh_terms: D000328:Adult; D002404:Catheterization; D020117:Cisapride; D004947:Esophagus / Q000187:drug effects; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000494:pharmacology*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D010477:Perfusion; D010880:Piperidines / Q000494:pharmacology*; D012463:Saliva / Q000737:chemistry / Q000187:drug effects* / Q000378:metabolism; D012471:Salivary Proteins and Peptides / Q000032:analysis / Q000187:drug effects; D013997:Time Factors
chemical_list: D005765:Gastrointestinal Agents; D010880:Piperidines; D012471:Salivary Proteins and Peptides; D020117:Cisapride